Trial Profile
A Single-Arm, Open-Label, Multicenter Clinical Trial With Nivolumab (BMS-936558) for Subjects With Histologically Confirmed Stage III (Unresectable) or Stage IV Melanoma Progressing Post Prior Treatment Containing an Anti-CTLA4 Monoclonal Antibody
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 23 Dec 2021
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications Malignant melanoma; Uveal melanoma
- Focus Adverse reactions
- Acronyms CheckMate 172
- Sponsors Bristol-Myers Squibb
- 30 Sep 2019 Results as off 23rd march 2018, evaluating safety and overall survival results in challenging subgroups that received nivolumab in CheckMate 172 published in the European Journal of Cancer
- 12 Aug 2019 Results (n=1008) assessing safety and efficacy of nivolumab in patients with melanoma, published in the European Journal of Cancer
- 19 Apr 2019 Status changed from active, no longer recruiting to completed.